Key facts
- Revolution Medicines stock rose 20% after its pancreatic cancer drug daraxonrasib showed positive Phase 3 results.
- Daraxonrasib is the first drug in a Phase 3 trial to push median survival past one year for previously treated metastatic pancreatic cancer.
- Patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months on standard chemotherapy.
- The drug cut the risk of death by 60% and reduced the risk of disease progression.
- Revolution Medicines plans to submit a rolling New Drug Application (NDA) to the FDA and proceed with global regulatory filings.
A Phase 3 trial success is a critical milestone in drug development, indicating that a new treatment has shown significant efficacy and safety in a large patient population. For pancreatic cancer, a disease with historically poor outcomes and limited treatment options, such a success represents a major step forward in potentially improving patient survival and quality of life. The positive results for daraxonrasib are particularly notable as it is the first drug to push median survival beyond one year in a Phase 3 trial for this indication.